Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02697877 · ClinicalTrials.gov registry record
Assessment of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements
A clinical trial, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- 183
- Enrollment target
NCT02697877: Completed study, sponsored by University of Illinois at Chicago.
NCT02697877 is a clinical trial that has completed, run by University of Illinois at Chicago. The registered enrollment target is 183 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02697877 has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- 183 participants
- Enrollment target
Study Summary
The aim of this study is to assess whether myocardial perfusion reserve, measured during routine clinically ordered regadenoson stress cardiac magnetic resonance (CMR) has prognostic value in predicting adverse cardiovascular events. Myocardial perfusion reserve will be measured with CMR by assessing blood flow through the coronary-sinus - the primary vein in the heart.
Interventions
- DRUG Regadenoson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2016-02 |
| Est. Completion | 2018-07 |
What the finished NCT02697877 record still lists
NCT02697877 is an observational study that tracks outcomes without assigning an intervention. The registered 183 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Regadenoson is the first listed.
NCT02697877 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02697877 about?
NCT02697877 is a clinical study titled "Assessment of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements". The aim of this study is to assess whether myocardial perfusion reserve, measured during routine clinically ordered regadenoson stress cardiac magnetic resonance (CMR) has prognostic value in predicting adverse cardiovascular events. Myocardial perfusion reserve will be measured with CMR by assessin...
What is the current status of trial NCT02697877?
This trial is currently completed. The enrollment target is 183 participants. The study started on 2016-02. Estimated completion is 2018-07.
What interventions are being tested in trial NCT02697877?
The interventions under investigation include: Regadenoson (DRUG).
Who is sponsoring clinical trial NCT02697877?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03859297 · 183 participants · NA
Mechanisms of Rumination Change in Adolescent Depression
- NCT04270591 · 183 participants · Phase 1
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- NCT06764615 · 183 participants · Phase 2
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- NCT06872684 · 183 participants · NA
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia